Company: TELO
Filing Date: 2025-11-12
Form Type: 8-K
Source: 0001493152-25-021712
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-12
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Reports That Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular
Iron in a Human Cell Line

New
live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes,
demonstrating potent cell penetration and iron-modulating activity - key to its broader epigenetic mechanism of action.

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO) Telomir-1 significantly exceeding Deferoxamine (DFO)

These
results extend the Company’s research into the relationship between metal-ion imbalance, oxidative stress, and epigenetic enzyme
regulation.

Study
Overview

The
evaluation utilized FerroOrange

Scientific
Context and Importance of the Findings

Iron
plays a vital role in human biology. It enables oxygen transport, mitochondrial energy generation, and DNA synthesis - processes
essential for growth and cellular development. In early life, iron is beneficial and tightly regulated by proteins such as ferritin transferrin ceruloplasmin

With
aging, however, these control systems become less efficient. Reactive forms of iron can accumulate within cells, participating in chemical
reactions that generate reactive oxygen species (ROS) accelerated aging neurodegenerative, metabolic, cardiovascular, and oncologic diseases

Cancer
biology further highlights the dual nature of iron. Many tumors depend on iron for rapid proliferation, using it to drive DNA replication,
sustained proliferation and energy production. Yet excessive intracellular iron also amplifies oxidative and methylation stress, disrupting
normal gene regulation and potentially promoting disease progression.

Understanding
how to safely modulate intracellular iron levels is therefore an important area of pre-clinical research. The ability of Telomir-1 to
enter cells and influence iron balance at low concentrations provides a basis for continued investigation into metal-ion homeostasis
and its link to cellular health and epigenetic control.

Key
Observations

  Telomir-1 reduced intracellular Fe²⁺ levels in a time- and dose-dependent manner at low-micromolar concentrations.                  
  Deferoxamine                                                                                                                        
  Telomir-1 has also been formulated with zinc ( Telomir-Zn) to enable a controlled intracellular exchange of metal ions—binding      

These
data support